A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

(2012) Nathalie Garçon et al.   Expert Review of Vaccines

Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis

(2011) Harish Nair et al.   LANCET

Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children

(2011) Timo Vesikari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody persistence and response to 2010–2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children

(2011) Vladimir Gilca et al.   VACCINE

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents

(2011) J. Garcia-Sicilia et al.   VACCINE

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months

(2010) Alfonso Carmona et al.   VACCINE

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Prepandemic Influenza Vaccine H5N1 (Split Virion, Inactivated, Adjuvanted) [Prepandrix™]

(2008) Natalie J Carter et al.   BIODRUGS

Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial

(2008) Hans C. Rümke et al.   VACCINE